Abstracts tagged "Response Criteria"

Abstract Number: 1368 • ACR Convergence 2025
Thrombocytosis Predicts Response to Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: Data from the Korean KOBIO Registry
Se Hee Kim¹ and kyung-Ann Lee², ¹Kyung Hee University College of Medicine, Seoul, Republic of Korea, ²Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea
Background/Purpose: This study aimed to evaluate the clinical characteristics of thrombocytosis, its relationship with disease activity and joint involvement, and its influence on the effectiveness…
Abstract Number: 2663 • ACR Convergence 2025
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome
David Beck¹, Mael Heiblig², Sinisa Savic³, Marcela ferrada⁴, Arsène Mekinian⁵, Onima Chowdhury⁶, Danielle Hammond⁷, Lachelle D. Weeks⁸, Carmelo Gurnari⁹, Yohei Kirino¹⁰, Sophie georgin-Lavialle¹¹, Sarah A. Buckley¹², Bryan G. harder¹², Sandra Goble¹² and Matthew Koster¹³, ¹Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ²Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ³University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁴University of Maryland, Bethesda, MD, ⁵Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁶Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, ⁷The University of Texas MD Anderson Cancer Center, Houston, TX, ⁸Dana Farber Cancer Institute, Boston, MA, ⁹Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, ¹⁰Yokohama City University Graduate School of Medicine, Yokohama, Japan, ¹¹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹²Sobi Inc., Waltham, MA, ¹³Mayo Clinic, Rochester, MN
Background/Purpose: VEXAS syndrome (Vacuoles, E1 ubiquitin-activating enzyme, X-linked, Autoinflammatory, Somatic) is a systemic disorder characterized by an overlap of hematologic and inflammatory features. Treatment poses…
Abstract Number: 1348 • ACR Convergence 2025
Real World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data from the European and Non-European Cohorts of the RA-BE-REAL Study
Rieke Alten¹, Gerd Burmester², Marco Matucci-Cerinic³, Jens Gerwien⁴, Walid Fakhouri⁴, Samuel Ogwu⁴, Ewa Haladyj⁴, Inmaculada De La Torre⁴, Bruno Fautrel⁵ and AJ Fernandez⁴, ¹SCHLOSSPARK KLINK, Teaching Hospital of University Medicine Berlin, Department of Internal Medicine and Rheumatology, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³University San Raffaele Milano, Milano, Milan, Italy, ⁴Eli Lilly and Company, Indiana Polis, IN, ⁵Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Here, we provide descriptive baseline characteristics and effectiveness outcomes of Baricitinib (BARI) and other ts/bDMARDs at 24-month (24M) in both European (EU) and non-European…
Abstract Number: 2644 • ACR Convergence 2025
Single Cell RNA-seq Profiling Reveals a Blood Monocyte Phenotype Associated with Response to TNF Inhibitor Therapy in RA Patients
Kathryne Marks¹, Alice Horisberger², Ifeoluwakiisi Adejoorin¹, Leah Santacroce¹, Mehreen Elahee³, Joan Bathon⁴, Kevin Wei⁵, Daniel Solomon⁶ and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Lausanne University Hospital (CHUV), Lausanne, Switzerland, ³Brigham and Women's Hospital, Wexford, PA, ⁴Columbia University, NEW YORK, NY, ⁵Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: TNF inhibitors (TNFi) are the most common biologic DMARD used to treat RA; however, no robust biomarkers have been established to predict likelihood of…
Abstract Number: 1286 • ACR Convergence 2025
Response to Hydroxychloroquine in Immune Thrombocytopenia in Childhood-Onset Systemic Lupus Erythematosus
Hamada Natour¹, Y. Ingrid Goh¹, Daniela Dominguez², Nicholas Gold¹, Lawrence Ng³, Andrea Knight⁴, Earl Silverman¹, Brian Feldman¹, Linda Hiraki¹ and Deborah Levy¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, Canada, ³The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: The management of immune thrombocytopenia in childhood-onset systemic lupus erythematosus (cSLE) is not standardized. We examined the efficacy and safety of hydroxychloroquine (HCQ) as…
Abstract Number: 2554 • ACR Convergence 2025
Real-World Observations on Symptom Response and Tolerability of Intravenous Immunoglobulin in Patients with Inflammatory Myopathies through a Nurse-Led Outcomes Monitoring Program in a Home Infusion Setting
Didem Saygin¹, Elizabeth Neal², Edward O'Bryan³, Alisha Smith, PharmD³, Leslie Myers³ and Timothy Walton³, ¹Rush University Medical Center, Chicago, IL, ²CSI Pharmacy, Nash, TX, ³CSI Pharmacy, Nash
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are autoimmune diseases typically characterized by muscle weakness. Intravenous Immunoglobulin (IVIg) is an effective immunomodulatory therapy in patients with refractory…
Abstract Number: 1115 • ACR Convergence 2025
Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes
Juliette quelain¹, Eleonore Mourre², Julien Henry¹, Rakiba Belkir³, Andrew Cope⁴, Debashis Sarker⁵, Yin Wu⁶, Matthaios Kapiris⁷, Aurelien Marabelle⁸, Caroline Robert⁸, Raphaele Seror⁹, Xavier Mariette¹⁰ and Samuel Bitoun¹, ¹APHP, PARIS, France, ²APHP, PARIS, ³PARIS, PARIS, France, ⁴King's College London, London, United Kingdom, ⁵Comprehensive Cancer Centre and Consultant Medical Oncologist at Guy's, St Thomas' and King's College Hospitals., London, United Kingdom, ⁶Honorary Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁷KCL, LONDON, United Kingdom, ⁸IGR, PARIS, France, ⁹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ¹⁰Université Paris-Saclay, Le Kremlin Bicetre, France
Background/Purpose: Approvals for immune checkpoint inhibitors (ICIs) have expanded, and triple therapy combining anti-PD-1, anti-CTLA-4, and anti-LAG3 have been evaluated with encouraging results. But they…
Abstract Number: 2456 • ACR Convergence 2025
Predictors of Real-World Remission in Patients with SLE Initiating Belimumab in the USA
Aarat M Patel¹, Renee L. Gennarelli², Temitope Bello², Ali Bonakdar² and Karen Worley³, ¹GSK, US Medical Affairs, Durham, NC, ²Cencora, Real-World Evidence, Conshohocken, PA, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA
Background/Purpose: The Definition Of Remission in SLE (DORIS) criteria were developed to align SLE remission definitions.1,2 Post hoc analyses of clinical trial data demonstrated that…
Abstract Number: 0642 • ACR Convergence 2025
Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
Paola Vidal Montal¹, Javier Narváez², Aina Fabregat³, Iñigo Rúa-Figueroa⁴, José María Pego-Reigosa⁵, Andrea Hernández-martín⁶, Clara Moriano⁷, Maria Garcia-Villanueva⁸, Sandra Garrote Corral⁹, Sergi Heredia¹⁰, Julia Martínez Barrio¹¹, Júlia Bernardez Moreno¹², Paloma Vela Casasempere¹³, Beatriz Tejera Segura¹⁴, Leyre Riancho¹⁵, Francisco Javier Novoa¹⁶, Vicenç Torrente-Segarra¹⁷, Maria Piqueras García¹⁸, Beatriz Frade Sosa¹⁹, José Gomez-Puerta²⁰, Consuelo Ramos Giraldez²¹, Tarek Salman Montes²², María Galindo-Izquierdo²³, EVA GLORIA TOMERO MURIEL²⁴, Jaime calvo²⁵, Jorge Juan Fragío Gil²⁶, Marta De la Rubia Navarro²⁷, Berta Magallares²⁸ and Irene Altabás-González²⁹, ¹Bellvitge University Hospital, Barcelona, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Department of Rheumatology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁴Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁵Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ⁶Hospital Universitario de Gran Canaria Dr Negrín, Las palmas, Spain, ⁷Hospital León, LEON, Castilla y Leon, Spain, ⁸Hospital Ramón y Cajal, Madrid, Spain, ⁹Hospital Ramón y Cajal, Madrid, ¹⁰Hospital Moisès Broggi, Barcelona, Spain, ¹¹Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ¹²Hospital de Sant Pau, Barcelona, Spain, ¹³Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁴Hospital Insular de Gran Canaria, Las palmas, Spain, ¹⁵Hospital de Sierrallana, Torrelavega, ¹⁶Hospital Insular de Gran Canaria, Las palmas, ¹⁷Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ¹⁸Servicio Murciano de Salud, Murcia, Spain, ¹⁹Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²⁰Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ²²Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²³Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ²⁴Hospital Universitario de la Princesa, Madrid, Spain, ²⁵Hospital de Araba, Vitoria, Spain, ²⁶Hospital General Universitario, Valencia, Spain, ²⁷Hospital de La Fe, Valencia, ²⁸Hospital de Sant Pau, Bareclona, ²⁹Complejo Hospitalario de Vigo, Vigo, Spain
Background/Purpose: The newly published ACR guidelines recommend initiating triple therapy for all patients with proliferative lupus nephritis (LN). While belimumab (BEL) has demonstrated efficacy in…
Abstract Number: 2402 • ACR Convergence 2025
High-Resolution Proteomic Profiling Validates BAFF Pathway Modulation and Reveals Novel Biomarker Signatures in Belimumab Treatment
Alexander Tsoi¹, Dionysis Nikolopoulos², Natalia Sherina³ and Ioannis Parodis¹, ¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ³Karolinska Institutet, Division of Rheumatology, Department of Medicine Solna, and Karolinska University Hospital, Stockholm, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Belimumab, a BAFF inhibitor, is an effective treatment for systemic lupus erythematosus (SLE), but biomarkers predicting treatment response remain elusive. We aimed to identify…
Abstract Number: 0777 • ACR Convergence 2025
Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)
Kevin Byram¹, Herman Mann², Danielle Hammond³, Sinisa Savic⁴, Yohei Kirino⁵, Carmelo Gurnari⁶, Mael Heiblig⁷, Thibault Comont⁸, Arsène Mekinian⁹, Mrinal Patnaik¹⁰, Lachelle D. Weeks¹¹, Gary Ho¹², Onima Chowdhury¹³, Adam Al-Hakim¹⁴, Scott Goldberg¹⁵, Marcela ferrada¹⁶, Sophie georgin-Lavialle¹⁷, Peter Grayson¹⁸, Emma Groarke¹⁹, Bhavisha Patel²⁰, Megan Sullivan²¹, Sarah A. Buckley²², Bryan G. harder²², Sandra Goble²², Matthew Koster¹⁰ and David Beck²³, ¹Vanderbilt University Medical Center, Nashville, TN, ²Institute of Rheumatology, Praha ², Czech Republic, ³The University of Texas MD Anderson Cancer Center, Houston, TX, ⁴University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁶Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, ⁷Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ⁸Centre Hospitalier Universitaire Toulouse Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, ⁹Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Dana Farber Cancer Institute, Boston, MA, ¹²New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ¹³Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, ¹⁴University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine,, Leeds, United Kingdom, ¹⁵New York University Grossman School of Medicine, Brooklyn, NY, ¹⁶University of Maryland, Bethesda, MD, ¹⁷Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ¹⁹National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ²⁰National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, ²¹Mayo Clinic Arizona, Scottsdale, AZ, ²²Sobi Inc., Waltham, MA, ²³Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY
Background/Purpose: VEXAS syndrome is a recently described severe disease characterized by a complex overlap of inflammatory and hematologic features. Due to the severity and refractory…
Abstract Number: 2375 • ACR Convergence 2025
Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
KURT OELKE¹, Emily Edson-Heredia², Sarah Ross³, Jennifer Marie Pustizzi⁴, Ali Sheikhi Mehrabadi⁴, Natalia Bello⁴, Frederick Murphy⁵, Shikha Singla⁶, Siba Raychaudhuri⁷, Philip J Mease⁸ and Arthur Kavanaugh⁹, ¹rheumatic disease center, Glendale, WI, ²eli lilly, indianapolis, ³Lilly, Indianapolis, IN, ⁴Eli Lilly, Indianapolis, IN, ⁵Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁶Medical College of Wisconsin, Milwaukee, WI, ⁷UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ⁸University of Washington, Seattle, WA, ⁹University of California, San Diego, School of Medicine, San Diego, CA

Background/Purpose: Ixekizumab (IXE) is a selective interleukin-17A antagonist that has proven effective in Phase 3 and 4 clinical trials for patients with psoriatic arthritis (PsA).Methods:…
Abstract Number: 0263 • ACR Convergence 2025
A Multicenter Retrospective Case Series of Patients with Susac Syndrome treated with Rituximab
Michelle Benjamin¹, Mattia Wruble Clark², Shamik Bhattacharyya³, Audra Horomanski¹ and Kristin Galetta⁴, ¹Stanford University, Palo Alto, CA, ²Mass General Brigham, Somerville, MA, ³Brigham and Women's Hospital, Malden, MA, ⁴Stanford Medical Center, Palo Alto
Background/Purpose: Susac Syndrome (SuS) is a rare immune-mediated vasculo-occlusive disease characterized by a triad of encephalopathy, hearing loss, and branched retinal artery occlusions. Deficits can…
Abstract Number: 2275 • ACR Convergence 2025
Agreement Between Two Rheumatoid Arthritis Response Measures Across b/ts DMARD Treatment Classes in a Large, Prospective Observational Study Supporting the Development and Clinical Validation of a Novel Blood-based Precision Medicine Test
Peter Taylor¹, Jason Carlson², Shirley Vu², Signe Fransen³, Diana Abdueva⁴ and Jeffrey Curtis⁵, ¹University of Oxford, Oxford, United Kingdom, ²Aqtual Inc, Hayward, CA, ³Aqtual, sf, CA, ⁴Aqtual, Hayward, CA, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Contemporary pharmacological management of rheumatoid arthritis (RA) is set within a treat-to-target framework. This requires quantitative, longitudinal assessments of disease activity with a view…
Abstract Number: 0260 • ACR Convergence 2025
Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research
Lachelle D. Weeks¹, Danielle Hammond², Sinisa Savic³, Mael Heiblig⁴, Onima Chowdhury⁵, Arsène Mekinian⁶, Carmelo Gurnari⁷, Radhakrishanan Ramchandren⁸, Sophie georgin-Lavialle⁹, Marcela ferrada¹⁰, Sarah A. Buckley¹¹, Bryan G. harder¹¹, Sandra Goble¹¹, David Beck¹² and Matthew Koster¹³, ¹Dana Farber Cancer Institute, Boston, MA, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁴Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ⁵Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, ⁶Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁷Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, ⁸University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹⁰University of Maryland, Bethesda, MD, ¹¹Sobi Inc., Waltham, MA, ¹²Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ¹³Mayo Clinic, Rochester, MN
Background/Purpose: VEXAS syndrome is a recently identified, severe systemic hemato-inflammatory disease with a complex and heterogeneous clinical presentation. The disease is associated with significant morbidity…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].